

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **CHARI**

Application No: **09/671,995**

Group Art Unit: **1642**

Filed: **September 29, 2000**

Examiner: **M. Tran, Ph.D.**

For: **Compositions and Methods for Treating Cancer Using  
Immunoconjugates and Chemotherapeutic Agents**

Docket No: 104322.198 US1

Assistant Commissioner of Patents  
Washington, DC 20231

**RECEIVED**

APR 16 2001

TECH CENTER 1600/2900


**Response to Restriction Requirement**

This Response is submitted in reply to the Restriction Requirement dated March 15, 2001, for which a response is due on or before April 15, 2001.

In response to the restriction requirement, Applicants elect Group III, claims 40-41, with traverse.

Pursuant to MPEP 821.04, Applicants respectfully request rejoinder of Group I, claims 1-32, with elected Group III. Applicants respectfully submit that a search for the claims in Group III will necessarily encompass a search for the claims in Group I, and will not place an undue burden on the Examiner.

Respectfully submitted,

  
Edward D. Grieff  
Registration No. 38,898

Date: April 11, 2001

Hale and Dorr LLP  
1455 Pennsylvania Avenue, NW  
Washington, DC 20004  
Phone: 202-942-8400

04/13/2001 SDIRETA1 00000001 080219 09671995

01 FC:103

666.00 CH

#6  
Linda  
4/19/01



PreAm dt A/  
#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **CHARI**

Application No: **09/671,995**

Group Art Unit: **1642**

Filed: **September 29, 2000**

Examiner: **M. Tran, Ph.D.**

For: **Compositions and Methods for Treating Cancer Using  
Immunoconjugates and Chemotherapeutic Agents**

Docket No: 104322.198 US1

Assistant Commissioner of Patents  
Washington, DC 20231

**RECEIVED**

APR 16 2001

TECH CENTER 1600/2900

**Preliminary Amendment**

Prior to consideration of the above application on the merits, Applicants respectfully request entry of the following claim amendments, without prejudice.

**IN THE CLAIMS:**

The pending claims and amendments to the claims are attached hereto.

**Remarks**

After entry of the amendment, claims 1-32, 40, 41 and 44-89 are pending.

Applicants respectfully submit that added claims 44-89 are supported by the originally filed claims and fall within the scope of elected Group III.

Claims 33-39, 42 and 43 have been canceled without prejudice, as directed to non-elected subject matter. Applicants reserve the right to file divisional applications directed to the non-elected subject matter.

Pursuant to MPEP 821.04, Applicants respectfully request rejoinder of Group I, claims 1-32, with elected Group III.